Evidence-based medicine: Worship of form and treatment of high blood pressure

Journal of General Internal Medicine

Volumn 15, Issue 10, 2000, Pages 755-756

  Psaty, Bruce M ^a   Rhoads, Caroline ^a   Furberg, Curt D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

DIURESIS; EVIDENCE BASED MEDICINE; HYPERTENSION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION REVIEW; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033764116     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2000.00814.x     Document Type: Review

References (15)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure
2. Failure of evidence-based medicine in the treatment of hypertension in older adults
3. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
4. Medical Research Council trial of treatment of hypertension in older adults: Principal results
5. Temporal patterns of anti-hypertensive medication use among older adults, 1989-1992: An effect of major clinical trials on clinical practice?
6. Antihypertensive medication use among recruits for the trial of nonpharmacologic interventions in the elderly (TONE)
7. Teaching residents evidence-based medicine skills: A controlled trial of effectiveness and assessment of durability
8. Health outcomes associated with anti-hypertensive therapies used as first-line agents: A systematic review and meta-analysis
9. Are research ethics committees behaving ethically? Some suggestions for improving performance and accountability
10. What makes clinical research ethical?
11. Surrogate endpoints, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease
12. Randomized clinical trials of antihypertensive drugs: All that glitters is not gold
13. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on a surrogate end point
14. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
15. Class effects: Are drugs within a class interchangeable?